We were able to achieve a selectivity of 19 (B001) and 24 (B002) with selected drug combinations when tested in BCR-ABL+ ALL xenograft derived patient cells (Figure 4 and Table S6). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.